Nuwellis, Inc. (NUWE)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Nuwellis, Inc. (NUWE)
Company Performance

Current Price

as of Oct 29, 2024

$1.82

P/E Ratio

N/A

Market Cap

$3.64M

Description

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Metrics

Overview

  • HQEden Prairie, MN
  • SectorHealth Technology
  • IndustryMedical Specialties
  • TickerNUWE
  • Price$1.82-12.50%

Trading Information

  • Market Cap$3.64M
  • Float99.99%
  • Average Daily Volume (1m)1,354,542
  • Average Daily Volume (3m)623,208
  • EPS-$181.62

Company

  • Revenue$9.01M
  • Rev Growth (1yr)5.73%
  • Net Income-$7.73M
  • Gross Margin67.18%
  • EBITDA Margin-102.32%
  • EBITDA-$2.25M
  • EV$1.69M
  • EV/Revenue0.19
  • P/EN/A
  • P/S0.08
  • P/BN/A
Documents
SEC Filings
8-K (2024-10-23)
8-K (2024-08-26)
8-K (2024-08-22)
8-K (2024-08-13)
8-K (2024-08-12)
8-K (2024-07-25)
8-K (2024-07-17)
8-K (2024-07-03)
8-K (2024-06-26)
8-K (2024-06-10)
8-K (2024-06-06)
8-K (2024-05-29)
8-K (2024-05-07)
8-K (2024-05-01)
8-K (2024-03-26)
8-K (2024-03-06)
8-K (2024-02-06)
8-K (2024-01-08)
8-K (2023-12-13)
8-K (2023-11-07)
8-K (2023-11-01)
8-K (2023-10-17)
8-K (2023-10-10)
8-K (2023-08-18)
8-K (2023-08-08)
8-K (2023-06-21)
8-K (2023-06-05)
8-K (2023-05-22)
8-K (2023-05-09)
8-K (2023-03-14)
8-K (2023-03-01)
8-K (2023-01-18)
8-K (2023-01-09)
8-K (2023-01-05)
10-Q (2024-08-13)
10-Q (2024-05-08)
10-Q (2023-11-07)
10-Q (2023-08-08)
10-Q (2023-05-09)
10-K (2024-03-11)
10-K (2023-03-03)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-07)
Earnings Report (2023-08-08)
Factset
Factset Business Description
Factset Street Account
Nuwellis reports Q3 EPS ($1.81) vs FactSet ($3.11) [3 est, ($3.24)-(3.00)] ($0.70, 0.00) (2023-11-07T13:02:08Z)
Nuwellis downgraded to neutral from buy at Ladenburg Thalmann ($0.67, 0.00) (2023-11-08T12:59:23Z)
Nuwellis announces pudblication of Aquadex ultrafiltration therapy data in Pediatric Nephrology ($0.72, 0.00) (2023-11-28T13:07:51Z)
Nuwellis announces pricing of $2.25M offering of Series J Convertible Preferred Stock and warrants through Lake Street and Maxim ($1.01, 0.00) (2023-10-13T12:42:41Z)